Sinai Chicago, ElixirTrials team up to bring trials into local care settings

Sinai Chicago and ElixirTrials on Tuesday announced a partnership to expand clinical trial access in underserved Chicago communities by embedding research opportunities inside Sinai’s care network. The deal aims to reduce barriers like transportation and mistrust while giving sponsors a new model for reaching more diverse patients.

Why it matters: - The partnership is designed to move clinical research closer to patients in communities that have historically been left out of trials. - Sinai Chicago and ElixirTrials say the model could improve access to new therapies, broaden representation in research, and create a scalable approach for community-based trials. - Clinical trial participation remains limited nationwide. The release says 88% of U.S. health centers lack the infrastructure to run trials, and fewer than 5% of patients enroll.

What happened: - Sinai Chicago and ElixirTrials announced a partnership on Tuesday, Sept. 30, 2026, in Chicago. - The organizations will integrate clinical trial opportunities into Sinai Chicago care settings. - The effort combines Sinai Chicago’s community-based care network with ElixirTrials’ research infrastructure, technology and operational support.

The details: - ElixirTrials provides a turnkey model that includes staffing, technology, regulatory support and operational workflows. - The model is intended to help community health systems conduct sponsor-grade clinical research at no upfront cost. - Sinai Chicago contributes clinical expertise, trusted patient relationships and a community presence across Chicago’s West and Southwest sides. - Patients will be able to access trial opportunities close to home while continuing care with providers they already know. - The partnership is also meant to address transportation barriers, awareness gaps and historical mistrust. - Sinai Chicago and ElixirTrials plan community-centered outreach, culturally relevant education, caregiver engagement and patient support throughout the research process. - The organizations will set up the full infrastructure, integrate the ElixirTrials Cauldron platform, train and support clinical teams, and partner with community groups to increase awareness. - The partners will identify clinical trials aligned with Sinai Chicago’s patient population. - For more information, visit Sinai Chicago and ElixirTrials.

Between the lines: - The agreement reflects a broader push to bring clinical research out of large academic medical centers and into community health systems. - Sinai Chicago gains a way to deepen its health equity and community research work without building trial infrastructure from scratch. - ElixirTrials gets a live example of its model for enabling trusted local health systems to run trials for sponsors. - The pitch is as much about trust as logistics: the companies are betting that familiar care settings can lift enrollment among patients who may not otherwise participate.

What's next: - Sinai Chicago and ElixirTrials are now building the operational setup needed to launch the program. - The organizations will continue working with caregivers and community partners to support participation. - Future trial opportunities will be matched to patient needs within Sinai Chicago’s network.

The bottom line: - The partnership aims to make clinical trials more accessible where patients already receive care, while giving researchers access to a more diverse pool of participants.